All In Biotech

Free tool

FAERS Monitor: Vanrafia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219208 or its brand name (Vanrafia, Atrasentan Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

101

Serious

30

30% of reports

Hospitalization

14

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective9
  • fatigue9
  • dizziness6
  • nausea6
  • peripheral swelling6
  • product dose omission issue6
  • swelling6
  • blood creatinine increased5
  • oedema5
  • rash5
  • renal impairment5
  • anaemia4
  • fluid retention4
  • oedema peripheral4
  • proteinuria4

Reports by year received

View as table
YearReports
20041
20051
20061
20071
20111
20122
20131
20142
20151
202546
202644

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
proteinuriaSignal443.816.8127
oedemaSignal519.28.269
fluid retentionSignal416.46.344
blood creatinine increasedSignal516.06.856
swellingSignal613.46.157
renal impairmentSignal512.45.342
peripheral swellingSignal68.13.731
oedema peripheralSignal46.82.615
anaemiaSignal44.41.77
product dose omission issueSignal64.22.012
dizzinessSignal62.51.24
fatigueSignal92.41.36
rash52.41.03
nausea61.60.71
drug ineffective91.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.